SRSF2 and myelodysplastic syndrome: For example, mutations in epigenetic regulators, e.g., TET2 or DNMT3A, can remain in the CHIP phase for many years, while modifications in spliceosome genes (e.g., SF3B1 and SRSF2) have a more rapid transformation to MDS [22].